Citations

Showing 10 of 108119 citations.

Eliminating Fighting and Head Hits from Hockey: Opportunities and Barriers
Smith, Aynsley M., Farrell, Kyle , Roberts, William O. , Moris, Mae R. , Farrell, Kyle J, Farrell, Kyle J , Stuart, Michael J.

Mayo Clinic

Current Sports Medicine Reports | January 29, 2019 | Volume: 18 | Issue: 1 | Pages: 35-40

10.1249/jsr.0000000000000556 | PMID 30624333 Get It

Abstract Removing fighting from ice hockey is an essential concussion prevention strategy that will improve the safety of the game at all levels.
Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Battat, Robert , Duijvestein, Marjolijn , Guizzetti, Leonardo , Choudhary, Daksh , Boland, Brigid S. , Dulai, Parambir S. , Parker, Claire E. , Nguyen, Tran M , Singh, Siddharth , Pai, Rish K. , Feagan, Brian G. , Sandborn, William J. , Guizzetti, L , Casteele, Niels Vande , Jairath, Vipul

Mayo Clinic

American Journal of Gastroenterology | January 29, 2019 | Volume: 114 | Issue: 5 | Pages: 733-745

10.14309/ajg.0000000000000111 | PMID 30694863 Get It

OBJECTIVES: Histologic remission is a potentially valuable means of assessing disease activity and treatment response in ulcerative colitis (UC). However, the efficacy of existing therapies to achieve this outcome is unclear. We performed a systematic review and meta-analysis of histologic outcomes in UC randomized controlled trials and examined the relationship between histologic and endoscopic outcomes. METHODS: MEDLINE, EMBASE, CENTRAL, and the Cochrane IBD Register were searched for randomized controlled trials of aminosalicylates, corticosteroids, immunosuppressives, biologics, and small molecules. Histologic and endoscopic remission and response data were independently extracted and pooled using binomial–normal random-effect or fixed-effect models. Pooled efficacy estimates were calculated as risk ratios (RRs) using the Mantel–Haenszel method. Univariable and multivariable random-effect meta-regression models examined factors associated with histologic remission. RESULTS: Seventy-four studies (68 induction and 7 maintenance) were identified. Topical aminosalicylate enemas [37.2%, 95% confidence interval (CI), 29.0–46.3] and suppositories (44.9%, 95% CI, 28.9–62.3) had the highest induction of histologic remission rates. Aminosalicylate enemas (RR = 4.14, 95% CI, 2.35–7.31), aminosalicylate suppositories (RR = 3.94, 95% CI, 1.26–12.32), and budesonide multimatrix (RR = 1.47, 95% CI 1.08–1.99) had higher histologic remission rates than placebo. Data were lacking for biologics and immunosuppressives. The pooled histologic remission rate for placebo in induction studies was 10.4% (95% CI, 7.1–15.2). Histologic and endoscopic remission correlated strongly ( r = 0.66; 95% CI, 0.50–0.78). In multivariate analysis of placebo-arm data, less severe clinical disease activity and corticosteroid use were associated with higher histologic remission rates. Similarly, mild clinical disease activity was associated with higher histologic remission rates when active-arm data were analyzed. CONCLUSIONS: Histologic remission rates for current UC treatments ranged from 15.0% to 44.9% according to drug class and patient population with the highest rates observed for topical aminosalicylates. Placebo remission rates were low with relatively narrow CIs. These data provide benchmarks to inform future trial design. Histologic remission is a potential treatment target in clinical practice.
Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis
Bajaj, Jasmohan S. , O’Leary, Jacqueline G. , Biggins, Scott W. , García–Tsao, Guadalupe , Kamath, Patrick S. , Maliakkal, Benedict, Fallon, Michael B. , Thuluvath, Paul J. , Vargas, Hugo E. , Subramanian, Ram, Reddy, K. Rajender , Vargas, Hugo E , Tandon, Puneeta , Wong, Florence , Lai, Jennifer C. , Thacker, Leroy R.

Mayo Clinic

American Journal of Gastroenterology | January 29, 2019 | Volume: 114 | Issue: 4 | Pages: 599-606

10.14309/ajg.0000000000000044 | PMID 30694868 Get It

OBJECTIVES: Antibiotic prophylaxis is recommended for prevention of the first episode of spontaneous bacterial peritonitis (SBP; primary prophylaxis 1°) and subsequent episodes (secondary prophylaxis 2°). We aimed to compare outcomes in cirrhotic inpatients on 1° vs 2° SBP prophylaxis. METHODS: Data from North American Consortium for the Study of End-Stage Liver Disease were evaluated for cirrhosis details, reasons for admission/medications, inpatient course recorded, and outcomes over 90 days. Outcomes (intensive care units, acute kidney injury, inpatient/90-day mortality) were compared between the 2 groups after propensity-matching on admission model for end-stage liver disease (MELD) score and serum albumin. RESULTS: Among the 2,731 patients enrolled, 305 were on 1° and 187 on 2° SBP prophylaxis. After propensity-matching, 154 patients remained in each group. Patients on 1° prophylaxis were more likely to have admission systemic inflammatory response syndrome ( P = 0.02), with higher intensive care unit admissions (31% vs 21%; P = 0.05) and inpatient mortality (19% vs 9%; P = 0.01) than the 2° prophylaxis group. Patients on 2° prophylaxis had higher total (22% vs 10%; P = 0004), readmission (16% vs 9%; P = 0.03), and nosocomial (6% vs 0.5%; P = 0.01) SBP rates with predominant Gram-negative organisms compared to 1° prophylaxis patients. At 90 days, 1° prophylaxis patients had a higher mortality (35% vs 22%; P = 0.02) and acute kidney injury incidence (48% vs 30%; P = 0.04) compared to 2° prophylaxis patients. DISCUSSION: In this inpatient cirrhosis study, despite prophylaxis, a high proportion of patients developed SBP, which was associated with mortality. Cirrhotic inpatients on 1° prophylaxis had worse outcomes than those on 2° prophylaxis when propensity-matched for the MELD score and serum albumin during the index admission and 90-day follow-up.
Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms
Goyal, Gaurav , Lau, Denise , Nagle, Alison M., Vassallo, Robert , Ryu, Jay H. , Davidge‐Pitts, Caroline , Tobin, W. Oliver , Liu, Minetta C. , Tobin, W Oliver , Goyal, Guarav , Vassallo, Robert , Ryu, Jay H , Rech, Karen L. , Koster, Matthew J. , Bennani, N. Nora , Shah, Meera , Go, Ronald S.

Mayo Clinic

Blood | January 29, 2019 | Volume: 133 | Issue: 14 | Pages: 1607-1610

10.1182/blood-2018-12-893917 | PMID 30696619 Get It

Inflammatory Bowel Disease: A Webliography
Gerberi, Dana , Gerberi, Danielle J

Mayo Clinic

Journal of Consumer Health on the Internet | January 29, 2019 | Volume: 22 | Issue: 4 | Pages: 352-361

10.1080/15398285.2018.1544822 Get It

Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions
Bastea, Ligia I. , Liou, Geou‐Yarh , Pandey, Veethika , Martinez, Alicia K. Fleming , Roemeling, Christina A. Von , Doeppler, Heike, Qiu, Yushi, Edenfield, Brandy , Copland, John A. , Störz, Peter , Fleming, Alicia K, von Roemeling, Christina A , Tun, Han W. , Liou, Geou-Yarh , Bastea, Ligia , Döppler, Heike, Li, Zhimin

Mayo Clinic

Cancer Research | January 29, 2019 | Volume: 79 | Issue: 7 | Pages: 1535-1548

10.1158/0008-5472.can-18-1153 | PMID 30696657 Get It

Abstract During development of pancreatic cancer, alternatively activated macrophages contribute to fibrogenesis, pancreatic intraepithelial neoplasia (PanIN) lesion growth, and generation of an immunosuppressive environment. Here, we show that the immunomodulatory agent pomalidomide depletes pancreatic lesion areas of alternatively activated macrophage populations. Pomalidomide treatment resulted in downregulation of interferon regulatory factor 4, a transcription factor for M2 macrophage polarization. Pomalidomide-induced absence of alternatively activated macrophages led to a decrease in fibrosis at PanIN lesions and in syngeneic tumors; this was due to generation of an inflammatory, immune-responsive environment with increased expression of IL1α and presence of activated (IFNγ-positive) CD4+ and CD8+ T-cell populations. Our results indicate that pomalidomide could be used to decrease fibrogenesis in pancreatic cancer and may be ideal as a combination treatment with chemotherapeutic drugs or other immunotherapies. Significance: These findings reveal new insights into how macrophage populations within the pancreatic cancer microenvironment can be modulated, providing the means to turn the microenvironment from immunosuppressive to immune-responsive.
Models and Studies of Aging: Executive Summary of a Report from the U13 Conference Series
Hurria, Arti , Carpenter, Christopher R. , McFarland, Frances, Lundebjerg, Nancy E., Cabo, Rafael de , Ferrucci, Luigi , Studenski, Stephanie A. , Barzilai, Nir , Kitzman, Dalane W. , Kuchel, George A. , Musi, Nicolas , Newman, John C., Rando, Thomas A. , Smith, Alexander K. , Kirkland, James L. , Yung, Raymond , Carpenter, Christopher R , Ferrucci, Luigi , de Cabo, Rafael , Kuchel, George A , Briggs, Josephine P. , Ix, Joachim H. , Newman, John C., Walston, Jeremy D

Mayo Clinic

Journal of the American Geriatrics Society | January 29, 2019 | Volume: 67 | Issue: 3 | Pages: 428-433

10.1111/jgs.15788 | PMID 30693953 Get It

The American Geriatrics Society convened a conference in Bethesda, Maryland, to explore models and studies of aging. This was the second of three conferences, supported by a U13 grant from the National Institute on Aging, to aid recipients of Grants for Early Medical/Surgical Specialists Transition to Aging Research (GEMSSTAR) in integrating geriatrics into their specialties. Recognizing that aging is the largest risk factor for multiple chronic diseases and age‐related loss of resilience, the conference organizers focused scientific sessions on how targeting age‐related mechanisms can delay, prevent, or reverse geriatric syndromes, age‐related chronic diseases, and loss of resilience. The rationale for studying models of aging as well as study designs, strategies, and challenges of studying human aging were reviewed. This article provides a summary of the full conference report, Models and Studies of Aging: Report from the U13 Conference Series, and summarizes key take‐home messages that were designed to support GEMSSTAR awardees in developing their research careers focused on aging research (see supplementary text for the full report). J Am Geriatr Soc 67:428–433, 2019.
Alteplase Instillation for Upper Urinary Tract Clot Dissolution
Manka, Madeleine, Lipworth, Roy , Heslop, Daniel, Sharma, Vidit , Husmann, Douglas A. , Westerman, Mary E. , Husmann, Douglas, Mahmoud, Ali, Westerman, Mary E

Mayo Clinic

Journal of Endourology Case Reports | January 29, 2019 | Volume: 5 | Issue: 1 | Pages: 16-18

10.1089/cren.2018.0088 | PMID 32760798 Get It

Abstract Background: We report the first case of instillation of alteplase, a tissue plasminogen activator, to dissolve occlusive upper urinary tract blood clot. Case Presentation: A 67-year-old Caucasian man with a solitary kidney became dialysis dependent because of upper urinary tract clot obstruction after ureteral stent placement for obstructing ureterolithiasis. After failure of more conservative measures, 10 mg of alteplase was instilled through nephrostomy tube daily for 2 consecutive days 30 minutes before manual irrigation with physiologic saline. After alteplase instillation, the occlusive blood clot dissolved with rapid improvement in urinary output and creatinine. Conclusions: Alteplase instillation through nephrostomy tube is a viable option to dissolve obstructing upper urinary tract blood clots.
Protein informatics combined with multiple data sources enriches the clinical characterization of novel TRPV4 variant causing an intermediate skeletal dysplasia
Hines, Stephanie L., Richter, John E. , Mohammad, Ahmed N. , Jain, Mahim , Caulfield, Thomas R. , Caulfield, Thomas R , Atwal, Paldeep S

Mayo Clinic

Molecular Genetics & Genomic Medicine | January 29, 2019 | Volume: 7 | Issue: 3 | Pages: No page available

10.1002/mgg3.566 | PMID 30693671 Get It

AbstractBackgroundTransient receptor potential cation channel subfamily V member 4 (TRPV4) is an ion channel permeable to Ca2+ that is sensitive to physical, hormonal, and chemical stimuli. This protein is expressed in many cell types, including osteoclasts, chondrocytes, and sensory neurons. As such, pathogenic variants of this gene are associated with skeletal dysplasias and neuromuscular disorders. Pathogenesis of these phenotypes is not yet completely understood, but it is known that genotype–phenotype correlations for TRPV4 pathogenic variants often are not present.MethodsNewly characterized, suspected pathogenic variant in TRPV4 was analyzed using protein informatics and personalized protein‐level molecular studies, genomic exome analysis, and clinical study.ResultsThis statement is demonstrated in the family of our proband, a 47‐year‐old female having the novel c.2401A>G (p.K801E) variant of TRPV4. We discuss the common symptoms between the proband, her father, and her daughter, and compare her phenotype to known TRPV4‐associated skeletal dysplasias.ConclusionsProtein informatics and molecular modeling are used to confirm the pathogenicity of the unique TRPV4 variant found in this family. Multiple data were combined in a comprehensive manner to give complete overall perspective on the patient disease and prognosis.